RUNX1 + RUNX2 Polyclonal Antibody, PE-Cy5 Conjugated
Cat# bs-1134R-PE-Cy5
Size : 100ul
Brand : Bioss
RUNX1 + RUNX2 Polyclonal Antibody, PE-Cy5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-1134R-PE-Cy5 |
| Product Name | RUNX1 + RUNX2 Polyclonal Antibody, PE-Cy5 Conjugated |
| Applications | WB, FCM |
| Reactivity | Human, Mouse, Rat, Rabbit, Guinea Pig |
| Predicted Reactivity | Dog, Cow, Sheep, Horse, Chicken |
| Specifications | |
| Conjugation | PE-Cy5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human RUNX2 |
| Immunogen Range | 202-300/521 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 860 |
| Swiss Prot | Q13950 |
| Subcellular location | Nucleus |
| Synonyms | CCD; AML3; CCD1; CLCD; OSF2; CBFA1; OSF-2; PEA2aA; PEBP2aA; CBF-alpha-1; Runt-related transcription factor 2; Acute myeloid leukemia 3 protein; Core-binding factor subunit alpha-1; Oncogene AML-3; Osteoblast-specific transcription factor 2; Polyomavirus enhancer-binding protein 2 alpha A subunit; PEA2-alpha A; PEBP2-alpha A; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core-binding factor alpha A subunit; RUNX2; PEBP2A |
| Background | Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |